Key result
NFATc2 deletion prevents progression to spontaneous AF in CREM mice, reducing incidence to 0%.
Why the study?
Activation of the NFAT signalling pathway contributes to atrial remodelling, but the role of NFATc2 in AF in humans and mouse models remained to be determined.
Does NFATc2 knockout prevent atrial fibrillation and atrial remodeling in CREM transgenic mice?
Does NFATc2 knockout prevent atrial fibrillation and atrial remodeling in CREM transgenic mice?
Absolute Event Rate: 0% vs 54%
p-value: p=<0.05
Genetic inhibition of NFATc2 prevents the progression of atrial fibrillation and associated atrial remodeling in a progressive AF mouse model, highlighting a potential therapeutic target.
AIMS: Abnormal intracellular calcium (Ca2+) handling contributes to the progressive nature of atrial fibrillation (AF), the most common sustained cardiac arrhythmia. Evidence in mouse models suggests that activation of the nuclear factor of activated T-cell (NFAT) signalling pathway contributes to atrial remodelling. Our aim was to determine the role of NFATc2 in AF in humans and mouse models. METHODS AND RESULTS: Expression levels of NFATc1-c4 isoforms were assessed by quantitative reverse transcription-polymerase chain reaction in right atrial appendages from patients with chronic AF (cAF). NFATc1 and NFATc2 mRNA levels were elevated in cAF patients compared with those in normal sinus rhythm (NSR). Western blotting revealed increased cytosolic and nuclear levels of NFATc2 in AF patients. Similar findings were obtained in CREM-IbΔC-X transgenic (CREM) mice, a model of progressive AF. Telemetry ECG recordings revealed age-dependent spontaneous AF in CREM mice, which was prevented by NFATc2 knockout in CREM:NFATc2-/- mice. Programmed electrical stimulation revealed that CREM:NFATc2-/- mice lacked an AF substrate. Morphometric analysis and histology revealed increased atrial weight and atrial fibrosis in CREM mice compared with wild-type controls, which was reversed in CREM:NFATc2-/- mice. Confocal microscopy showed an increased Ca2+ spark frequency despite a reduced sarcoplasmic reticulum (SR) Ca2+ load in CREM mice compared with controls, whereas these abnormalities were normalized in CREM:NFATc2-/- mice. Western blotting revealed that genetic inhibition of Ca2+/calmodulin-dependent protein kinase II-mediated phosphorylation of S2814 on ryanodine receptor type 2 (RyR2) in CREM:RyR2-S2814A mice suppressed NFATc2 activation observed in CREM mice, suggesting that NFATc2 is activated by excessive SR Ca2+ leak via RyR2. Finally, chromatin immunoprecipitation sequencing from AF patients identified Ras and EF-hand domain-containing protein (Rasef) as a direct target of NFATc2-mediated transcription. CONCLUSION: Our findings reveal activation of the NFAT signalling pathway in patients of Chinese and European descent. NFATc2 knockout prevents the progression of AF in the CREM mouse model.
No takes yet. Share an insight, caveat, or question.
Ni et al. (2021) studied Atrial fibrillation. Genetic inhibition of NFATc2 (NFATc2 knockout) vs. CREM transgenic mice (disease model) and wild-type mice was evaluated on Incidence of spontaneous atrial fibrillation at 5 months of age (p=<0.05). Genetic deletion of NFATc2 prevented the progression of atrial ectopic activity to spontaneous atrial fibrillation in CREM mice, reducing the incidence of sAF at 5 months from 54% to 0%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: